{"address1": "One Amgen Center Drive", "city": "Thousand Oaks", "state": "CA", "zip": "91320-1799", "country": "United States", "phone": "805 447 1000", "fax": "805 447 1010", "website": "https://www.amgen.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00e7et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert A. Bradway", "age": 60, "title": "Chairman, CEO & President", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 5487475, "fmt": "5.49M", "longFmt": "5,487,475"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 43693576, "fmt": "43.69M", "longFmt": "43,693,576"}}, {"maxAge": 1, "name": "Mr. Peter H. Griffith", "age": 64, "title": "Executive VP & CFO", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": {"raw": 2574004, "fmt": "2.57M", "longFmt": "2,574,004"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 245771, "fmt": "245.77k", "longFmt": "245,771"}}, {"maxAge": 1, "name": "Mr. Esteban  Santos", "age": 55, "title": "Executive Vice President of Operations", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 2521941, "fmt": "2.52M", "longFmt": "2,521,941"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 8232750, "fmt": "8.23M", "longFmt": "8,232,750"}}, {"maxAge": 1, "name": "Dr. David M. Reese M.D.", "age": 60, "title": "Executive VP & Chief Technology Officer", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 2833393, "fmt": "2.83M", "longFmt": "2,833,393"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 4932458, "fmt": "4.93M", "longFmt": "4,932,458"}}, {"maxAge": 1, "name": "Mr. Murdo  Gordon", "age": 56, "title": "Executive VP of Global Commercial Operations", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 2717562, "fmt": "2.72M", "longFmt": "2,717,562"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 2469817, "fmt": "2.47M", "longFmt": "2,469,817"}}, {"maxAge": 1, "name": "Mr. Matthew C. Busch", "age": 49, "title": "Chief Accounting Officer & VP of Finance", "yearBorn": 1974, "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mike  Zahigian", "title": "Senior VP & Chief Information Officer", "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. James E. Bradner M.D.", "age": 51, "title": "Executive VP of Research and Development & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Arvind  Sood", "title": "Vice President of Investor Relations", "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jonathan P. Graham", "age": 62, "title": "Executive VP, General Counsel & Secretary", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 2440307, "fmt": "2.44M", "longFmt": "2,440,307"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 2105468, "fmt": "2.11M", "longFmt": "2,105,468"}}], "auditRisk": 2, "boardRisk": 8, "compensationRisk": 2, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1706745600, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 294.85, "open": 294.85, "dayLow": 289.72, "dayHigh": 295.0, "regularMarketPreviousClose": 294.85, "regularMarketOpen": 294.85, "regularMarketDayLow": 289.72, "regularMarketDayHigh": 295.0, "dividendRate": 9.0, "dividendYield": 0.0309, "exDividendDate": 1707955200, "payoutRatio": 0.6821, "fiveYearAvgDividendYield": 2.96, "beta": 0.617, "trailingPE": 23.308247, "forwardPE": 13.629213, "volume": 3341055, "regularMarketVolume": 3341055, "averageVolume": 2649359, "averageVolume10days": 4203900, "averageDailyVolume10Day": 4203900, "bid": 290.1, "ask": 292.8, "bidSize": 800, "askSize": 900, "marketCap": 157748903936, "fiftyTwoWeekLow": 211.71, "fiftyTwoWeekHigh": 329.72, "priceToSalesTrailing12Months": 5.595917, "fiftyDayAverage": 293.8978, "twoHundredDayAverage": 259.5955, "trailingAnnualDividendRate": 8.52, "trailingAnnualDividendYield": 0.02889605, "currency": "USD", "fromCurrency": null, "toCurrency": null, "lastMarket": null, "coinMarketCapLink": null, "algorithm": null, "tradeable": false, "enterpriseValue": 209418207232, "profitMargins": 0.23828, "floatShares": 533550150, "sharesOutstanding": 535177984, "sharesShort": 9295065, "sharesShortPriorMonth": 9043268, "sharesShortPreviousMonthDate": 1703808000, "dateShortInterest": 1706659200, "sharesPercentSharesOut": 0.0174, "heldPercentInsiders": 0.00233, "heldPercentInstitutions": 0.80633, "shortRatio": 3.8, "shortPercentOfFloat": 0.0174, "impliedSharesOutstanding": 541868992, "category": null, "bookValue": 11.649, "priceToBook": 24.990986, "fundFamily": null, "legalType": null, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "earningsQuarterlyGrowth": -0.525, "netIncomeToCommon": 6717000192, "trailingEps": 12.49, "forwardEps": 21.36, "pegRatio": 2.56, "lastSplitFactor": "2:1", "lastSplitDate": 943228800, "enterpriseToRevenue": 7.429, "enterpriseToEbitda": 11.987, "52WeekChange": 0.19477963, "SandP52WeekChange": 0.21495235, "lastDividendValue": 2.13, "lastDividendDate": 1700092800, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AMGN", "underlyingSymbol": "AMGN", "shortName": "Amgen Inc.", "longName": "Amgen Inc.", "firstTradeDateEpochUtc": 424704600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "9376b97e-b428-3231-ba0b-142b20481cb4", "messageBoardId": "finmb_24816", "gmtOffSetMilliseconds": -18000000, "currentPrice": 291.12, "targetHighPrice": 380.0, "targetLowPrice": 185.0, "targetMeanPrice": 305.41, "targetMedianPrice": 317.5, "recommendationMean": 2.4, "recommendationKey": "buy", "numberOfAnalystOpinions": 22, "totalCash": 10944000000, "totalCashPerShare": 20.456, "ebitda": 17469999104, "totalDebt": 64612999168, "quickRatio": 0.99, "currentRatio": 1.649, "totalRevenue": 28189999104, "debtToEquity": 1036.794, "revenuePerShare": 52.692, "returnOnAssets": 0.10321, "returnOnEquity": 1.35793, "freeCashflow": 6542875136, "operatingCashflow": 8471000064, "earningsGrowth": -0.526, "revenueGrowth": 0.198, "grossMargins": 0.83778, "ebitdaMargins": 0.61972, "operatingMargins": 0.15678, "financialCurrency": "USD"}